Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Short Interest Down 51.7% in April
by Jessica Moore · The Cerbat GemNewron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF – Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 78,634 shares, a decline of 51.7% from the April 15th total of 162,794 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Newron Pharmaceuticals Price Performance
Newron Pharmaceuticals stock remained flat at $20.00 during trading hours on Friday. The stock’s fifty day moving average is $16.17 and its 200-day moving average is $11.74. Newron Pharmaceuticals has a 52-week low of $9.10 and a 52-week high of $20.00.
About Newron Pharmaceuticals
Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.
Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.